Your email has been successfully added to our mailing list.

×
0.000925925925925961 0.000925925925925961 0.0003086419753088 0.00123456790123476 0.00277777777777788 0.00771604938271605 0.0120370370370371 0.00802469135802463
Stock impact report

US Supreme Court declines to hear patent dispute over Bausch blockbuster diarrhea drug [Yahoo! Finance Canada]

Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA) 
Last teva pharmaceutical industries limited american depositary shares earnings: 2/13 04:01 pm Check Earnings Report
US:NYSE Investor Relations: ir.tevapharm.com
The justices declined to hear an appeal by Norwich Pharmaceuticals of a lower court's ruling that its proposed generic would infringe patents owned by Bausch unit Salix Pharmaceuticals for using Xifaxan to treat the liver-related brain disorder hepatic encephalopathy. In doing so, the justices let the lower court's ruling stand. Xifaxan has been approved by the U.S. Food and Drug Administration to treat traveler's diarrhea and irritable bowel syndrome and can also be used to prevent hepatic encephalopathy. Bausch earned more than $1.8 billion from Xifaxan sales in 2023, according to a company filing with the U.S. Securities and Exchange Commission. Bausch has separately agreed to allow Xifaxan generics from Teva Pharmaceuticals, Sun Pharmaceuticals and Sandoz starting in 2028 after settling related patent disputes. Salix in 2020 sued New York state-based Norwich over its proposed generic of Xifaxan. A Delaware federal judge decided in 2022 that the generic would infringe three Show less Read more
Impact Snapshot
Event Time:
TEVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for TEVA alerts
Opt-in for
TEVA alerts

from News Quantified
Opt-in for
TEVA alerts

from News Quantified